Inventor · Lexington, MA, US

Peter U. Park

29Patents
7h-index
35Co-inventors
65Inventor score

Filing activity: Oct 16, 2007 → Nov 14, 2022

Most-cited inventions

PatentTitleAreaCited byStatus
US8153765B2 Anti-CD38 antibodies for the treatment of cancer Physics 60 Active
US8790649B2 EGFR-binding molecules and immunoconjugates thereof Chemistry; Metallurgy 18 Active
US10875894B2 Multimeric bicyclic peptide ligands Chemistry; Metallurgy 16 Active
US8765917B2 CD37-binding molecules and immunoconjugates thereof Physics 14 Active
US9346887B2 CD37-binding molecules and immunoconjugates thereof Physics 9 Active
US11180531B2 Bicyclic peptide ligands specific for Nectin-4 Emerging Cross-Sectional Technologies 7 Active
US9555112B2 Monoclonal antibodies against HER2 epitope and methods of use thereof Chemistry; Metallurgy 7 Active
US9447189B2 CD37-binding molecules and immunoconjugates thereof Chemistry; Metallurgy 7 Active
US11261214B2 Bicyclic peptide ligand specific for CD137 Human Necessities 6 Active
US9173961B2 CD20 antibodies and uses thereof Chemistry; Metallurgy 6 Active
US11613560B2 Bicyclic peptide ligands specific for OX40 Chemistry; Metallurgy 5 Active
US11453703B2 Heterotandem bicyclic peptide complexes Chemistry; Metallurgy 5 Active
US11453702B2 Bicyclic peptide ligands specific for Nectin-4 Emerging Cross-Sectional Technologies 5 Active
US10202460B2 CD37-binding molecules and immunoconjugates thereof Physics 5 Active
US10556958B2 CD37-binding molecules and immunoconjugates thereof Chemistry; Metallurgy 5 Active
US12049520B2 Bicyclic peptide ligands specific for CD137 Human Necessities 4 Active
US11542304B2 Multimeric bicyclic peptide ligands Chemistry; Metallurgy 4 Active
US11912792B2 Bicyclic peptide ligands specific for nectin-4 Emerging Cross-Sectional Technologies 4 Active
US10947317B2 NaPi2b-targeted antibody-drug conjugates and methods of use thereof Chemistry; Metallurgy 4 Active
US9738720B2 Monoclonal antibodies against HER2 epitope and methods of use thereof Chemistry; Metallurgy 3 Active
US9233171B2 Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate Chemistry; Metallurgy 2 Active
US9125896B2 EGFR-binding molecules and immunoconjugates thereof Chemistry; Metallurgy 1 Active
US9808528B2 Protein-polymer-drug conjugates and methods of using same Chemistry; Metallurgy 1 Active
US11466095B2 CD37-binding molecules and immunoconjugates thereof Physics 1 Active
US11518812B2 Monoclonal antibodies against HER2 epitope and methods of use thereof Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.